bullish
3SBio Inc (1530 HK): Hair Product Acts as the Savior; Marginal Growth of Flagship Drug
424 Views01 Dec 2022 21:38
SUMMARY
- Mandi, OTC alopecia drug of 3SBio Inc (1530 HK), reported revenue growth of 42% y/y in 1H22 and gained 70bps market share over the last six months.
- With the resurgence of COVID-19 in China interrupting the regular operations of outpatient services at medical institutions, 3SBio’s performance is expected to be affected in near-term.
- 3SBio is preparing to launch its new drug nalfuraphine hydrochloride orally disintegrating tablets for liver and kidney disease pruritus in China.
Get started on the Smartkarma Research Network with a complimentary Preview Pass to:
- Unlock all research summaries
- Follow top, independent analysts
- Receive personalised alerts and emails
- Access Briefings, Analytics, and Events
Upgrade anytime to our paid plans for full-length research, real-time analyst discussions, and more.
Join a thriving community of 45,000+ investors, including the top global asset managers managing over $13trn in assets.
or
Already have an account? Sign In Now
Discussions
(Paid Plans Only)
Rising
Tina Banerjee
Global Healthcare Analyst
- 3SBio Inc (1530 HK): Hair Product Acts as the Savior; Marginal Growth of Flagship Drug01 Dec 2022
- 3SBio Inc (1530 HK): Core Biopharmaceutical Portfolio On A Double-Digit Growth Path17 Jun 2022
x